<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Sci Rep</journal-id><journal-id journal-id-type="iso-abbrev">Sci Rep</journal-id><journal-title-group><journal-title>Scientific Reports</journal-title></journal-title-group><issn pub-type="epub">2045-2322</issn><publisher><publisher-name>Nature Publishing Group UK</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39730388</article-id><article-id pub-id-type="pmc">PMC11680766</article-id><article-id pub-id-type="publisher-id">78059</article-id><article-id pub-id-type="doi">10.1038/s41598-024-78059-1</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Gastrointestinal carriage of carbapenemase-producing enterobacterales among inpatient and outpatient children in Kenya</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Githii</surname><given-names>Susan</given-names></name><address><email>susan.githii@yahoo.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Maingi</surname><given-names>John M.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Nyaga</surname><given-names>Teresia</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ndungu</surname><given-names>Cecilia</given-names></name><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Nyongesa</surname><given-names>Kelvin Wangira</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Musyoki</surname><given-names>Abednego Moki</given-names></name><address><email>Musyoki.abednego@ku.ac.ke</email></address><xref ref-type="aff" rid="Aff5">5</xref></contrib><aff id="Aff1"><label>1</label>National Public Health Laboratory, Upperhill, Kenyatta National Hospital Grounds, 20750-00202 Nairobi, Kenya </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05p2z3x69</institution-id><institution-id institution-id-type="GRID">grid.9762.a</institution-id><institution-id institution-id-type="ISNI">0000 0000 8732 4964</institution-id><institution>Department of Biochemistry, Microbiology and Biotechnology, School of Pure and Applied Sciences, </institution><institution>Kenyatta University, </institution></institution-wrap>43844-00100 Nairobi, Kenya </aff><aff id="Aff3"><label>3</label>Department of Medical Laboratory, Murang&#x02019;a County Referral Hospital, 69-10200 Murang&#x02019;a, Kenya </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/053sj8m08</institution-id><institution-id institution-id-type="GRID">grid.415162.5</institution-id><institution-id institution-id-type="ISNI">0000 0001 0626 737X</institution-id><institution>Department of Medical Research, </institution><institution>Kenyatta National Hospital, </institution></institution-wrap>P.O Box 20723-00202, Nairobi, Kenya </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05p2z3x69</institution-id><institution-id institution-id-type="GRID">grid.9762.a</institution-id><institution-id institution-id-type="ISNI">0000 0000 8732 4964</institution-id><institution>Department of Medical Laboratory Science, School of Health Sciences, </institution><institution>Kenyatta University, </institution></institution-wrap>43844-00100 Nairobi, Kenya </aff></contrib-group><pub-date pub-type="epub"><day>28</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="pmc-release"><day>28</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="collection"><year>2024</year></pub-date><volume>14</volume><elocation-id>30684</elocation-id><history><date date-type="received"><day>11</day><month>7</month><year>2024</year></date><date date-type="accepted"><day>28</day><month>10</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Gastrointestinal carriage of antimicrobial-resistant bacteria, especially carbapenemase-producing Enterobacterales (CPE), presents a critical public health threat globally. However, in many resource-constrained countries, epidemiological data on CPE is limited. Here, we assessed gastrointestinal carriage and associated factors of CPE among inpatient and outpatient children (&#x02264;&#x02009;5 years). This hospital-based cross-sectional study was conducted at Thika Level 5 Hospital in Kenya from February to June 2023. In total, 540 participants were recruited from outpatient (270) and inpatient (270) children, excluding those admitted for &#x0003c;&#x02009;48&#x000a0;h and outpatients with &#x02264;&#x02009;3 months hospitalization history. Demographic data were collected using a questionnaire, and stool or swab samples were cultured following standard microbiology methods. Automated platforms were used for isolates identification and antimicrobial susceptibility testing. Gastrointestinal carriage rate of CPE was 9.6%, 95% confidence interval (CI): 6.39&#x02013;13.79% (26/270) among the inpatients and 5.9%, 95% CI: 3.42&#x02013;9.45% (16/270) among the outpatients. The carbapenemase-producing Enterobacterales were predominated by multidrug-resistant <italic>Escherichia coli</italic> from inpatients (22/22, 100%) and outpatients (8/10, 80%). The colonization rate was higher among inpatients who were presenting with chills (aOR&#x02009;=&#x02009;10.57, <italic>p</italic>&#x02009;=&#x02009;0.008). We report a high gastrointestinal carriage of CPE among children (&#x02264;&#x02009;5 years). Strict adherence to colonization screening, and antimicrobial stewardship policies are critical to control CPE dissemination in the current study area and beyond.</p><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1038/s41598-024-78059-1.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Gastrointestinal carriage</kwd><kwd>Carbapenem-resistant Enterobacterales</kwd><kwd>Carbapenemase-producing enterobacterales</kwd><kwd>Multidrug-resistant</kwd><kwd>Risk factors</kwd></kwd-group><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Medical research</kwd><kwd>Risk factors</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Nature Limited 2024</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par5">Antimicrobial resistance (AMR) remains a formidable public health challenge globally. In 2019, there were an estimated 4.95&#x000a0;million deaths associated with bacterial AMR, including 1.27&#x000a0;million attributable deaths, with the burden disproportionately higher in Sub-Saharan Africa<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>. Worsening of the situation is expected by 2050, with a projected yearly burden of 10&#x000a0;million deaths and 100&#x000a0;billion US dollars in economic loss<sup><xref ref-type="bibr" rid="CR2">2</xref></sup>. Antimicrobial-resistant bacteria, particularly carbapenem-resistant strains, are frequently associated with high morbidity, increased length of hospital stay, and mortality<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>. Since their introduction in the early 1980s, carbapenems emerged as the preferred treatment for bacterial infections, especially those caused by multidrug-resistant (MDR) Gram-negative bacteria (GNB), due to their high effectiveness and minimal toxicity<sup><xref ref-type="bibr" rid="CR4">4</xref></sup>. In recent years, however, the global surge in resistance, attributed to its overuse and misuse, has negatively affected the clinical relevance of carbapenems<sup><xref ref-type="bibr" rid="CR5">5</xref></sup>. To date, carbapenem-resistant bacteria, including Enterobacterales, <italic>Pseudomonas aeruginosa</italic>, and <italic>Acinetobacter baumannii</italic>, tops the list of World Health Organization (WHO) global priority pathogens for the development of newer antimicrobial agents<sup><xref ref-type="bibr" rid="CR6">6</xref></sup>.</p><p id="Par6">Carbapenem resistance occurs through decreased membrane permeability, overexpression of efflux pumps, drug target modification, and production of carbapenemases. Carbapenemases are chromosomally or plasmid-encoded enzymes that hydrolyze the carbapenems and are the chief resistance mechanism in this antibiotic class<sup><xref ref-type="bibr" rid="CR7">7</xref></sup>. The global clinically significant carbapenemases, including <italic>Klebsiella pneumoniae</italic> Carbapenemase (KPC), New Delhi metallo-&#x003b2;-lactamase-type 1 (NDM-1), Verona Integron Encoded Metallo-&#x003b2;-Lactamase (VIM), and Imipenemase Metallo-&#x003b2;-Lactamase (IMP)<sup><xref ref-type="bibr" rid="CR8">8</xref></sup> are generally located within different integrons associated with mobile plasmids or transposons, facilitating the transfer of resistance genes between bacteria. Oxacillinase (OXA)-48 and its related variants are also globally relevant because of their &#x003b2;-lactamase inhibitor resistance<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>.</p><p id="Par7">Carbapenem-resistant (CR) bacteria are frequently MDR, which substantially limits therapeutic options and are associated with high mortality rates (33&#x02013;50%)<sup><xref ref-type="bibr" rid="CR9">9</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref></sup>. The triple combination of polymyxin, carbapenem, and rifampin or tigecycline, as an option, is faced with efficacy uncertainty due to emerging resistance. The newer antibiotics, including ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam, imipenem-cilastatin-sulbactam, plazomicin, eravacycline, and cefiderocol, are expensive, have limited high-quality clinical data, and are faced with delays in susceptibility testing methods approval and the complexity of antibacterial spectra<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>.</p><p id="Par8">Despite the adoption of the Global Action Plan on AMR by the World Health Assembly in May 2015, carbapenem resistance in Africa is seemingly increasing, with reported rates ranging from less than 1&#x02013;60% among GNB<sup><xref ref-type="bibr" rid="CR14">14</xref>&#x02013;<xref ref-type="bibr" rid="CR16">16</xref></sup>. The gastrointestinal tract can serve as a hidden reservoir for carbapenem-resistant Enterobacterales (CRE), such as <italic>Klebsiella</italic>,<italic> Escherichia</italic>,<italic> Aeromonas</italic>,<italic> Serratia</italic>, <italic>Citrobacter,</italic>&#x000a0;<italic>Proteus</italic>, <italic>Morganella</italic>,<italic> Providencia</italic>, and <italic>Enterobacter.</italic> Asymptomatic CRE colonization may precede infection among susceptible persons, including those in intensive care units (ICU), artificially ventilated, catheterized, and with weakened immunity<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>, and has been identified as a significant risk factor for the development of CRE infections<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>. Colonization can also increase the risk of the resistance traits disseminating to other bacteria, escalating AMR.</p><p id="Par9">The predictors of CRE colonization are exposure to antibiotics such as carbapenems, cephalosporins, fluoroquinolones and vancomycin, presence of an invasive device, number of hospital admissions, admission from another facility, and admission from or discharge to a long-term care facility<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>. However, in many Sub-Saharan African countries, especially in Kenya<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>, with inadequate potable water, poor sanitation, poor adherence to antimicrobial stewardship policies, and the majority of healthcare facilities lacking microbiology laboratories capable of reporting AMR, there is limited data on gastrointestinal CRE carriage to inform infection prevention and control interventions. Here, we aimed to determine the gastrointestinal carriage of CPE and risk factors among children under five years in inpatient and outpatient departments in a Kenyan hospital.</p></sec><sec id="Sec2"><title>Materials and methods</title><sec id="Sec101"><title>Study setting, design, and population</title><p id="Par11">The study was conducted at Thika Level 5 Hospital, located in Thika town, approximately 50&#x000a0;km from Nairobi City, Kenya, and serving as a referral facility for Kiambu County. The facility has a 467-bed capacity, serves an average of 800 to 1000 outpatients daily, and receives patients from neighbouring counties, including Nairobi City, Muranga, Kirinyaga, and Machakos. It was a cross-sectional study among children (&#x02264;&#x02009;5 years) admitted to the hospital&#x02019;s pediatric ward and those seeking healthcare services in the outpatient department, whereby consecutive and systematic random sampling techniques, respectively, were employed. We included participants with or without gastrointestinal illnesses, excluding outpatients with a hospitalization history within three months and inpatients admitted for less than 48&#x000a0;h. The research was carried out following the Declaration of Helsinki, obtaining informed consent from each participating child&#x02019;s parent or guardian, ensuring the participants&#x02019; well-being, and promptly communicating all critical results with physicians. The participant&#x02019;s data and samples were assigned unique codes to ensure confidentiality.</p></sec><sec id="Sec3"><title>Samples collection</title><p id="Par12">A structured questionnaire, administered through face-to-face interviews, was used to collect the participants&#x02019; demographic and clinical characteristics data for putative CRE carriage risk factors analysis. Stool samples, collected in clean and dry wide-necked containers, and rectal swabs collected in Cary-Blair transportation medium (Hopebio, Qingdao, China) from children unable to provide stool were transported in a cool box to the Thika Level 5 Hospital microbiology laboratory for processing within two hour-holding time.</p></sec><sec id="Sec100"><title>Phenotypic screening of carbapenemase-producing Enterobacterales</title><p id="Par14">Initially, we screened stool/swab samples for carbapenem-resistant Enterobacterales (CRE) using MacConkey agar supplemented with 1&#x000a0;&#x000b5;g/ml of meropenem and incubated at 37&#x000a0;&#x000b0;C for 18&#x02013;24&#x000a0;h<sup><xref ref-type="bibr" rid="CR19">19</xref></sup>. Growth of colonies on the antibiotic-supplemented MacConkey agar was interpreted as positive-CRE carriage, whereas the absence of growth was considered CRE carriage-negative. <italic>E. coli</italic> ATCC 25,922 and <italic>Klebsiella pneumoniae</italic> ATCC 700,603 were the positive and negative control organisms, respectively.</p><p id="Par15">The CRE positive isolates were confirmed for carbapenemase production using the modified carbapenem inactivation method (mCIM) following the CLSI (2023) guidelines<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>. The test isolate was transferred from an overnight culture using a sterile wire loop into a tube containing 2&#x000a0;ml Tryptic Soy Broth (TSB). The suspension was vortexed for 10&#x000a0;min, a 10&#x000a0;&#x000b5;g meropenem disk immersed, and incubated for 4&#x000a0;h at 35&#x000a0;&#x000b0;C. <italic>E. coli</italic> ATCC 25,922 suspensions, equivalent to 0.5 McFarland standard, was prepared using normal saline, inoculated on Muller Hinton Agar (MHA) plates, and air-dried for 10&#x000a0;min. Subsequently, we removed the meropenem disc from the test isolate-TSB culture using a sterile 10 &#x000b5;L loop to the MHA and incubated the plate for 18 to 24&#x000a0;h at 35&#x000a0;&#x000b0;C.</p><p id="Par16">Isolates with 6&#x02013;15&#x000a0;mm inhibition zone diameter were interpreted as carbapenemase (producers) positive, considered to have produced carbapenemase enzyme that hydrolyzed the meropenem antibiotic, resulting in no inhibition or limited growth inhibition of the meropenem-susceptible <italic>E. coli</italic> ATCC 25,922. A&#x02009;&#x02265;&#x02009;19&#x000a0;mm inhibition zone diameter was interpreted as carbapenemase negative, indicating that the test isolate did not produce the carbapenemase to hydrolyze the meropenem disk, resulting in growth inhibition of the meropenem-susceptible <italic>E. coli</italic>. Isolates with 16&#x02013;18&#x000a0;mm and &#x02265;&#x02009;19&#x000a0;mm inhibition zone diameters and pinpoint colonies were considered indeterminate, and their mCIM test was repeated<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>. We used <italic>E. coli</italic> ATCC 25,922 (non-carbapenemase producer) and <italic>Klebsiella pneumoniae</italic> ATCC 700,603 (carbapenemase-producer) as the quality control organisms.</p></sec><sec id="Sec102"><title>Isolates identification and antibiotic susceptibility testing</title><p id="Par17">The isolates that turned positive for carbapenemase production were identified using matrix-assisted laser desorption ionization-time of flight mass spectrometry ((MALDI-TOF MS) (Bruker Daltonik GmbH, Bremen, Germany). VITEK&#x000a0;2 (bioMK2 bi S.A., NS. A, Nu, Germany) was used for antimicrobial susceptibility testing. The choice and interpretation of antimicrobial tested, including cefepime, ceftriaxone, cefuroxime, ceftazidime, cefotaxime, meropenem, ciprofloxacin, gentamicin, amikacin, colistin, trimethoprim-sulfamethoxazole, ampicillin, and piperacillin-tazobactam, were based on CLSI (2023) guidelines. <italic>Pseudomonas aeruginosa</italic> (ATCC 27853) and <italic>Escherichia coli</italic> (25922) served as the quality control organisms<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>.</p></sec><sec id="Sec103"><title>Colistin susceptibility testing</title><p id="Par18">This study used the broth microdilution (BMD) method for colistin susceptibility testing, as recommended by the CLSI 2023. Four tubes containing calcium magnesium Muller Hinton Broth were labelled 1,2, 4&#x000a0;&#x000b5;g/ml and 0&#x000a0;&#x000b5;g/ml (control), corresponding to colistin discs added, and the tubes were gently vortexed for 30&#x000a0;min to allow the colistin to elute from the disc. We prepared a 0.5 MacFarland standard equivalent suspension of each test organism, and sequentially 50&#x000a0;&#x000b5;l added to tubes 0, 1, 2 and 4&#x000a0;&#x000b5;g/ml, plated the original inoculum on a blood agar (BA) plate using a ten (10) &#x000b5;l loop for purity check, and incubated the plates and tubes at 35&#x000a0;&#x000b0;C for 16&#x02013;20&#x000a0;hours. For the test to be valid, colonies on the BA plate were to be pure with the control tube (0&#x000a0;&#x000b5;g/ml) showing turbidity. The minimum inhibitory concentration (MIC) of &#x02264;&#x02009;2&#x000a0;&#x000b5;g/ml was considered intermediate and &#x02265;&#x02009;4&#x000a0;&#x000b5;g/ml resistant, as per the CLSI, 2023, which does not provide colistin &#x0201c;susceptible&#x0201d; interpretation due to variability in testing methods and clinical outcomes. <italic>E. coli</italic> ATCC 25,922 and <italic>Proteus mirabilis</italic> were used as control organisms.</p></sec><sec id="Sec104"><title>Statistical analysis</title><p id="Par19">We analyzed the data obtained using Stata version 13 (STATA Corporation, College Station, TX, USA). The data was analyzed for normality using Shapiro-Wilk test. The frequencies and percentages were used to present the categorical data, while the means and medians were used for the continuous data, and these were displayed in tables and figures. The study used bivariable logistic regression to determine the association between the CPE gastrointestinal carriage and the participant&#x02019;s demographic and clinical characteristics. Variables having a p-value&#x02009;&#x02264;&#x02009;0.2 were subjected to further analysis by multivariable logistic regression to assess the independence of the associations, with p-value&#x02009;&#x02264;&#x02009;0.05 and a corresponding 95% confidence interval (CI) considered statistically significant. We defined multidrug resistance as resistance to at least one antibiotic in at least three antimicrobial classes<sup><xref ref-type="bibr" rid="CR21">21</xref></sup> and multiple antibiotic resistance indices (MARI) as a ratio of the number of antibiotics to which a bacterial isolate was resistant and the total number of antibiotics tested<sup><xref ref-type="bibr" rid="CR22">22</xref></sup>.</p></sec></sec><sec id="Sec7"><title>Results</title><sec id="Sec8"><title>Demographic and clinical characteristics of study participants</title><p id="Par20">This study sampled a total of 540 children (&#x02264;&#x02009;5 years), equally drawn from outpatients and inpatients. The majority of the participants were males (outpatients: 53.3%, 144/270; inpatients: 50.4%, 136/270), aged&#x02009;&#x02264;&#x02009;24 months (outpatients: 73.3%, 198/270; inpatients: 76.7%, 207/270) and had antibiotics exposure within three months of the sample collection (inpatients: 54.1%, 146/270; outpatients: 71.1%, 192/270), Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>.</p><p id="Par21">
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Demographic and clinical characteristics of study participants.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Variable</th><th align="left" rowspan="2">Category</th><th align="left" colspan="2">Proportion, <italic>n</italic> (%)</th></tr><tr><th align="left">Inpatients</th><th align="left">Outpatients</th></tr></thead><tbody><tr><td align="left" colspan="4">Age</td></tr><tr><td align="left"/><td align="left">&#x02264;&#x02009;24 months</td><td char="." align="char">207 (76.7)</td><td char="." align="char">198 (73.3)</td></tr><tr><td align="left"/><td align="left">&#x0003e;&#x02009;24 months</td><td char="." align="char">63 (23.3)</td><td char="." align="char">72 (26.7)</td></tr><tr><td align="left" colspan="4">Gender</td></tr><tr><td align="left"/><td align="left">Male</td><td char="." align="char">136 (50.4)</td><td char="." align="char">144 (53.3)</td></tr><tr><td align="left"/><td align="left">Female</td><td char="." align="char">134 (49.6)</td><td char="." align="char">126 (46.7)</td></tr><tr><td align="left" colspan="4">Clinical presentation</td></tr><tr><td align="left"/><td align="left">Vomiting</td><td char="." align="char">49 (18.1)</td><td char="." align="char">99 (36.7)</td></tr><tr><td align="left"/><td align="left">Chills</td><td char="." align="char">3 (1.1)</td><td char="." align="char">13 (4.8)</td></tr><tr><td align="left"/><td align="left">Diarrhoea</td><td char="." align="char">42 (15.6)</td><td char="." align="char">97 (35.9)</td></tr><tr><td align="left"/><td align="left">Headache</td><td char="." align="char">3 (1.1)</td><td char="." align="char">2 (0.7)</td></tr><tr><td align="left"/><td align="left">Respiratory illness</td><td char="." align="char">76 (28.1)</td><td char="." align="char">144 (53.3)</td></tr><tr><td align="left"/><td align="left">Fever</td><td char="." align="char">68 (25.4)</td><td char="." align="char">136 (50.6)</td></tr><tr><td align="left" colspan="4">Antibiotics use in the past 3 months</td></tr><tr><td align="left"/><td align="left">Yes</td><td char="." align="char">146 (54.1)</td><td char="." align="char">192 (71.1)</td></tr><tr><td align="left"/><td align="left">No</td><td char="." align="char">124 (45.9)</td><td char="." align="char">78 (28.9)</td></tr><tr><td align="left" colspan="4">Source of antibiotics</td></tr><tr><td align="left"/><td align="left">Chemist</td><td char="." align="char">37 (25.3)</td><td char="." align="char">35 (13.0)</td></tr><tr><td align="left"/><td align="left">Healthcare facility</td><td char="." align="char">109 (74.7)</td><td char="." align="char">157 (58.1)</td></tr><tr><td align="left" colspan="4">Used antibiotics prescribed by the clinician</td></tr><tr><td align="left"/><td align="left">Yes</td><td char="." align="char">83 (30.7)</td><td char="." align="char">87 (32.2)</td></tr><tr><td align="left"/><td align="left">No</td><td char="." align="char">187 (69.3)</td><td char="." align="char">183 (67.8)</td></tr><tr><td align="left" colspan="4">Completed the last antibiotic dose treatment</td></tr><tr><td align="left"/><td align="left">Yes</td><td char="." align="char">196 (72.6)</td><td char="." align="char">108 (39.6)</td></tr><tr><td align="left"/><td align="left">No</td><td char="." align="char">74 (27.4)</td><td char="." align="char">162 (60.4)</td></tr><tr><td align="left" colspan="4">Source of domestic water</td></tr><tr><td align="left"/><td align="left">Municipal water</td><td char="." align="char">254 (94.1)</td><td char="." align="char">241 (89.3)</td></tr><tr><td align="left"/><td align="left">Borehole water</td><td char="." align="char">16 (5.9)</td><td char="." align="char">29 (10.7)</td></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec105"><title>CPE gastrointestinal carriage</title><p id="Par22">Gastrointestinal carriage rate of CPE was 9.6%, 95% confidence interval (CI): 6.39&#x02013;13.79% (26/270) among the inpatients and 5.9%, 95% CI: 3.42&#x02013;9.45% (16/270) among the outpatients, Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>b. All the carbapenem-resistant Enterobacterales (CRE) isolates were carbapenemase producers. The spectrum of the carbapenemase-producing Enterobacterales (CPE) included five bacterial species recovered from outpatients and four from inpatients and was predominated by carbapenemase-producing <italic>Escherichia coli</italic> (CPEC) (inpatients: 22/26, 84.6%; outpatients: 10/16, 62.5%)), Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>a. There was a co-carriage of <italic>E. coli</italic> and <italic>Klebsiella pneumoniae</italic> among inpatients (1/270, 0.4%). CPE, including <italic>Enterobacter cloacae</italic> and <italic>Klebsiella variicola</italic>, were not isolated from outpatients, whereas <italic>Citrobacter freundii</italic>,<italic> Enterobacter bugandensis</italic> and <italic>Proteus mirabilis</italic> were absent among the hospitalized children, Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>a.</p><p id="Par23">
<fig id="Fig1"><label>Fig. 1</label><caption><p>Gastrointestinal carriage of CPE among the study participants. <italic> IP</italic> inpatients,<italic> OP</italic> outpatients, # number, % percent,<italic> CPE</italic> carbapenem-resistant Enterobacterales.</p></caption><graphic xlink:href="41598_2024_78059_Fig1_HTML" id="d33e723"/></fig>
</p></sec><sec id="Sec11"><title>CPE antimicrobial susceptibility profiles</title><p id="Par29">Here, we presented the antimicrobial susceptibility profile of carbapenemase-producing <italic>E. coli</italic> (CPEC) isolates, as there were only a few proportions of the other CPE isolates whose analysis could have yielded unreliable conclusions. Resistance to third-generation cephalosporins (3GCs) was 100% in both inpatient and outpatient children, Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>. Aminoglycosides resistance was highest in CPEC isolates from inpatients (32%) compared with those from outpatients (10%), whereas the non-susceptibility to monobactam (aztreonam) was observed at 100% among outpatients and inpatients. Generally, the lowest antimicrobial resistance was in aminoglycosides (10&#x02013;32%), and all CPEC isolates were susceptible to colistin, Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>.</p><p id="Par30">
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Antimicrobial susceptibility profiles of carbapenemase-producing <italic>E. coli</italic>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Antibiotics class</th><th align="left">Antibiotics</th><th align="left">Phenotype</th><th align="left">Outpatients n&#x02009;=&#x02009;10</th><th align="left">Inpatients n&#x02009;=&#x02009;22</th></tr></thead><tbody><tr><td align="left" rowspan="2">Penicillin</td><td align="left">AMP</td><td align="left">R</td><td align="left">100%</td><td align="left">100%</td></tr><tr><td align="left">TZP</td><td align="left">R</td><td align="left">40%</td><td align="left">45%</td></tr><tr><td align="left">2GC</td><td align="left">CXM</td><td align="left">R</td><td align="left">100%</td><td align="left">100%</td></tr><tr><td align="left" rowspan="3">3GC</td><td align="left">CTX</td><td align="left">R</td><td align="left">100%</td><td align="left">100%</td></tr><tr><td align="left">CAZ</td><td align="left">R</td><td align="left">100%</td><td align="left">100%</td></tr><tr><td align="left">CRO</td><td align="left">R</td><td align="left">100%</td><td align="left">100%</td></tr><tr><td align="left">4GC</td><td align="left">FEP</td><td align="left">R</td><td align="left">60%</td><td align="left">91%</td></tr><tr><td align="left" rowspan="2">AMINO</td><td align="left">AMK</td><td align="left">R</td><td align="left">10%</td><td align="left">32%</td></tr><tr><td align="left">GEN</td><td align="left">R</td><td align="left">10%</td><td align="left">32%</td></tr><tr><td align="left">Quinolones</td><td align="left">CIP</td><td align="left">R</td><td align="left">50%</td><td align="left">50%</td></tr><tr><td align="left">Sulfonamides</td><td align="left">SXT</td><td align="left">R</td><td align="left">100%</td><td align="left">95%</td></tr><tr><td align="left">Carbapenem</td><td align="left">MEM</td><td align="left">R</td><td align="left">100%</td><td align="left">100%</td></tr><tr><td align="left">Polymyxins</td><td align="left">CST</td><td align="left">R</td><td align="left">0%</td><td align="left">0%</td></tr><tr><td align="left">Monobactam</td><td align="left">ATM</td><td align="left">R</td><td align="left">100%</td><td align="left">100%</td></tr></tbody></table><table-wrap-foot><p><italic>AMP</italic> ampicillin,<italic> TZP</italic> piperacillin/tazobactam,<italic> CXM</italic> cefuroxime,<italic> CTX</italic> cefotaxime,<italic> CAZ</italic> ceftazidime,<italic> CRO</italic> ceftriaxone,<italic> FEP</italic> cefepime,<italic> AMK</italic> amikacin,<italic> GEN</italic> gentamicin,<italic> CIP</italic> ciprofloxacin,<italic> SXT</italic> trimethoprim/sulfamethoxazole,<italic> MEM</italic> meropenem,<italic> CST</italic> colistin,<italic> ATM</italic> aztreonam,<italic> S</italic> susceptible,<italic> R</italic> resistant,<italic> 2GC</italic> second-generation cephalosporin,<italic> 3GC</italic> third-generation cephalosporin,<italic> 4GC</italic> fourth-generation cephalosporin.</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec12"><title>MDR carbapenemase-producing <italic>E. coli</italic> isolates</title><p id="Par32">All CPEC isolates from inpatient (22/22, 100%) and 80% of those recovered from outpatient (8/10) were multidrug-resistant but remained susceptible to colistin, Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>. Multiple antibiotic resistance indices (MARI) were high, ranging from 0.23 to 0.46.</p><p id="Par33">
<table-wrap id="Tab3"><label>Table 3</label><caption><p>MDR carbapenemase-producing <italic>E. coli</italic> isolates.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Multidrug resistance phenotype</th><th align="left" colspan="2">MDR isolates</th><th align="left" rowspan="2">#</th><th align="left" rowspan="2">MARI</th></tr><tr><th align="left">IP, <italic>n</italic> (%)</th><th align="left">OP, <italic>n</italic> (%)</th></tr></thead><tbody><tr><td align="left">AMP-TZP/CXM-CTX-CAZ-CRO-FEP/MEM/SXT</td><td align="left">1 (4.5)</td><td align="left">2 (20.0)</td><td align="left">4</td><td align="left">0.31</td></tr><tr><td align="left">AMP-TZP/CXM-CTX-CAZ-CRO-FEP/CIP/SXT</td><td align="left">1 (4.5)</td><td align="left">1 (10.0)</td><td align="left">4</td><td align="left">0.31</td></tr><tr><td align="left">AMP/CXM-CTX-CAZ-CRO-FEP/MEM/CIP/SXT</td><td align="left">1 (4.5)</td><td align="left">1 (10.0)</td><td align="left">5</td><td align="left">0.38</td></tr><tr><td align="left">AMP/CXM-CTX-CAZ-CRO-FEP/MEM/AMK-GEN/CIP/SXT</td><td align="left">1 (4.5)</td><td align="left">1 (10.0)</td><td align="left">6</td><td align="left">0.46</td></tr><tr><td align="left">AMP-TZP/CXM-CTX-CAZ-CRO-FEP/MEM/AMK-GEN/CIP/SXT</td><td align="left">4 (18.2)</td><td align="left">0 (0.0)</td><td align="left">6</td><td align="left">0.46</td></tr><tr><td align="left">AMP/CXM-CTX-CAZ-CRO-FEP/MEM/SXT</td><td align="left">3 (13.6)</td><td align="left">0 (0.0)</td><td align="left">4</td><td align="left">0.31</td></tr><tr><td align="left">AMP/CXM-CTX/SXT</td><td align="left">3 (13.6)</td><td align="left">0 (0.0)</td><td align="left">3</td><td align="left">0.23</td></tr><tr><td align="left">AMP-TZP/CXM-CTX-CAZ-CRO-FEP/MEM/CIP/SXT</td><td align="left">2 (9.1)</td><td align="left">0 (0.0)</td><td align="left">5</td><td align="left">0.38</td></tr><tr><td align="left">AMP/CXM-CTX-CAZ-CRO-FEP/SXT</td><td align="left">2 (9.1)</td><td align="left">0 (0.0)</td><td align="left">3</td><td align="left">0.23</td></tr><tr><td align="left">AMP/CXM-CTX-CAZ-CRO-FEP/MEM/GEN/SXT</td><td align="left">1 (4.5)</td><td align="left">0 (0.0)</td><td align="left">5</td><td align="left">0.38</td></tr><tr><td align="left">AMP/CXM-CTX/MEM/SXT</td><td align="left">1 (4.5)</td><td align="left">0 (0.0)</td><td align="left">4</td><td align="left">0.31</td></tr><tr><td align="left">AMP/CXM-CTX-CAZ-CRO-FEP/MEM/AMK/CIP/SXT</td><td align="left">1 (4.5)</td><td align="left">0 (0.0)</td><td align="left">5</td><td align="left">0.38</td></tr><tr><td align="left">AMP-TZP/CXM-CTX-CAZ-CRO-FEP/MEM/AMK-GEN/SXT</td><td align="left">1 (4.5)</td><td align="left">0 (0.0)</td><td align="left">5</td><td align="left">0.38</td></tr><tr><td align="left">AMP/CXM-CTX-CAZ-CRO/CIP/SXT</td><td align="left">0 (0.0)</td><td align="left">2 (20.0)</td><td align="left">4</td><td align="left">0.31</td></tr><tr><td align="left">AMP/CXM-CTXCAZ-CRO-FEP/SXT</td><td align="left">0 (0.0)</td><td align="left">1(10.0)</td><td align="left">3</td><td align="left">0.23</td></tr><tr><td align="left">MDR, n (%)</td><td align="left">22 (100.0)</td><td align="left">8 (80.0)</td><td align="left"/><td align="left"/></tr></tbody></table><table-wrap-foot><p><italic>AMP</italic> ampicillin,<italic> TZP</italic> piperacillin/tazobactam,<italic> CRX</italic> cefuroxime,<italic> CXM</italic> cefuroxime,<italic> CTX</italic> cefotaxime,<italic> CAZ</italic> ceftazidime,<italic> CRO</italic> ceftriaxone,<italic> FEP</italic> cefepime,<italic> AMK</italic> amikacin,<italic> GEN</italic> gentamicin,<italic> CIP</italic> ciprofloxacin,<italic> SXT</italic> trimethoprim/sulfamethoxazole,<italic> CST</italic> colistin, # Number of antimicrobial classes resistant,<italic> MARI</italic> multiple antibiotic resistance index,<italic> MDR</italic> multidrug-resistant,<italic> OP</italic> outpatient,<italic> IP</italic> inpatient.</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec13"><title>Factors associated with gastrointestinal carriage of the CPE</title><sec id="Sec14"><title>Patient characteristics associated with CRE among children under five years</title><p id="Par35">Those who presented with chills symptoms were four times more likely to have CRE compared to those without chills, cOR&#x02009;=&#x02009;4.38, 95% CI: 1.35&#x02013;14.25, <italic>p</italic>&#x02009;=&#x02009;0.027. Multivariable model established that those with chills symptom were four times likely to have CRE, aOR&#x02009;=&#x02009;4.03, 95% CI: 1.22&#x02013;13.37, <italic>p</italic>&#x02009;=&#x02009;0.023 as shown in Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>.</p><p id="Par36">
<table-wrap id="Tab4"><label>Table 4</label><caption><p>Patient characteristics associated with CRE among children under five years.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Characteristics</th><th align="left" colspan="2">CRE</th><th align="left" rowspan="2">Total <italic>n</italic>(%)</th><th align="left" rowspan="2">cOR (95% CI) </th><th align="left" rowspan="2"><italic>P</italic>-value</th><th align="left" rowspan="2">aOR (95% CI) </th><th align="left" rowspan="2"><italic>P</italic>- value</th></tr><tr><th align="left">Yes <italic>n</italic>(%)</th><th align="left">No (%)</th></tr></thead><tbody><tr><td align="left" colspan="8">Gender</td></tr><tr><td align="left">&#x000a0;Male</td><td align="left">24 (58.5)</td><td align="left">255 (51.2)</td><td align="left">279 (51.8)</td><td align="left">1.35 (0.71&#x02013;2.57)</td><td align="left">0.418</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Female</td><td align="left">18 (41.5)</td><td align="left">243 (48.8)</td><td align="left">261 (48.2)</td><td align="left">Ref</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left" colspan="8">Age</td></tr><tr><td align="left">&#x000a0;&#x02264;&#x02009;24 months</td><td align="left">27 (65.9)</td><td align="left">378 (75.8)</td><td align="left">405 (75.0)</td><td align="left">0.62 (0.31&#x02013;1.22)</td><td align="left">0.188</td><td align="left">0.66 (0.33&#x02013;1.31)</td><td align="left">0.234</td></tr><tr><td align="left">&#x000a0;25&#x02013;59 months</td><td align="left">14 (34.1)</td><td align="left">121 (24.2)</td><td align="left">135 (25.0)</td><td align="left">Ref</td><td align="left"/><td align="left">Ref</td><td align="left"/></tr><tr><td align="left" colspan="8">Symptoms</td></tr><tr><td align="left" colspan="8">&#x000a0;Vomiting</td></tr><tr><td align="left">&#x000a0;&#x000a0;Yes</td><td align="left">15 (36.6)</td><td align="left">133 (26.7)</td><td align="left">148 (27.4)</td><td align="left">1.59 (0.82&#x02013;3.09)</td><td align="left">0.202</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;&#x000a0;No</td><td align="left">26 (63.4)</td><td align="left">366 (73.3)</td><td align="left">392 (72.6)</td><td align="left">Ref</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left" colspan="8">&#x000a0;Chills</td></tr><tr><td align="left">&#x000a0;&#x000a0;Yes</td><td align="left">4 (9.8)</td><td align="left">12 (2.4)</td><td align="left">16 (3.0)</td><td align="left">4.38 (1.35&#x02013;14.25)</td><td align="left">0.027*</td><td align="left">4.03 (1.22&#x02013;13.37)</td><td align="left">
<bold>0.023*</bold>
</td></tr><tr><td align="left">&#x000a0;&#x000a0;No</td><td align="left">38 (90.2)</td><td align="left">486 (97.6)</td><td align="left">524 (97.0)</td><td align="left">Ref</td><td align="left"/><td align="left">Ref</td><td align="left"/></tr><tr><td align="left" colspan="8">&#x000a0;Diarrhoea</td></tr><tr><td align="left">&#x000a0;&#x000a0;Yes</td><td align="left">10 (24.4)</td><td align="left">129 (25.9)</td><td align="left">139 (25.8)</td><td align="left">0.92 (0.44&#x02013;1.94)</td><td align="left">0.499</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;&#x000a0;No</td><td align="left">31 (75.6)</td><td align="left">369 (74.1)</td><td align="left">400 (74.2)</td><td align="left">Ref</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left" colspan="8">&#x000a0;Headache</td></tr><tr><td align="left">&#x000a0;&#x000a0;Yes</td><td align="left">0</td><td align="left">5 (1.0)</td><td align="left">5 (0.9)</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;&#x000a0;No</td><td align="left">41 (100)</td><td align="left">492 (99.0)</td><td align="left">533 (99.1)</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left" colspan="8">&#x000a0;Respiratory illness</td></tr><tr><td align="left">&#x000a0;&#x000a0;Yes</td><td align="left">22 (53.7)</td><td align="left">198 (39.8)</td><td align="left">220 (40.9)</td><td align="left">1.75 (0.92&#x02013;3.32)</td><td align="left">0.099</td><td align="left">1.75 (0.92&#x02013;3.33)</td><td align="left">0.090</td></tr><tr><td align="left">&#x000a0;&#x000a0;No</td><td align="left">19 (46.3)</td><td align="left">299 (60.2)</td><td align="left">318 (59.1)</td><td align="left">Ref</td><td align="left"/><td align="left">Ref</td><td align="left"/></tr><tr><td align="left" colspan="8">&#x000a0;Fever</td></tr><tr><td align="left">&#x000a0;&#x000a0;Yes</td><td align="left">18 (43.9)</td><td align="left">186 (37.5)</td><td align="left">204 (38.0)</td><td align="left">1.30 (0.66&#x02013;2.48)</td><td align="left">0.409</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;&#x000a0;No</td><td align="left">23 (56.1)</td><td align="left">310 (62.5)</td><td align="left">336 (62.0)</td><td align="left">Ref</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left" colspan="8">Medication in last 3 months</td></tr><tr><td align="left">&#x000a0;Yes</td><td align="left">28 (68.3)</td><td align="left">310 (62.1)</td><td align="left">338 (62.6)</td><td align="left">1.31 (0.66&#x02013;2.60)</td><td align="left">0.504</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;No</td><td align="left">13 (31.7)</td><td align="left">189 (37.9)</td><td align="left">202 (37.4)</td><td align="left">Ref</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left" colspan="8">Source of medication</td></tr><tr><td align="left">&#x000a0;Chemist</td><td align="left">7 (25.0)</td><td align="left">65 (21.0)</td><td align="left">72 (21.3)</td><td align="left">1.26 (0.51&#x02013;3.08)</td><td align="left">0.631</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Healthcare facility</td><td align="left">21 (75.0)</td><td align="left">245 (79.0)</td><td align="left">266 (78.7)</td><td align="left">Ref</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left" colspan="8">Drugs from chemist with prescription</td></tr><tr><td align="left">&#x000a0;Yes</td><td align="left">0</td><td align="left">33 (50.8)</td><td align="left">33 (45.8)</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;No</td><td align="left">7 (100)</td><td align="left">32 (49.2)</td><td align="left">39 (54.2)</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left" colspan="8">Gives antibiotics only when prescribed</td></tr><tr><td align="left">&#x000a0;Yes</td><td align="left">14 (34.1)</td><td align="left">181 (36.4)</td><td align="left">195 (36.2)</td><td align="left">0.91 (0.46&#x02013;1.77)</td><td align="left">0.866</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;No</td><td align="left">27 (65.9)</td><td align="left">316 (63.6)</td><td align="left">343 (63.8)</td><td align="left">Ref</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left" colspan="8">Completed last antibiotic treatment</td></tr><tr><td align="left">&#x000a0;Yes</td><td align="left">21 (52.5)</td><td align="left">281 (56.4)</td><td align="left">302 (56.1)</td><td align="left">0.85 (0.45&#x02013;1.63)</td><td align="left">0.624</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;No</td><td align="left">21 (47.5)</td><td align="left">217 (43.6)</td><td align="left">238 (43.9)</td><td align="left">Ref</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left" colspan="8">Source of drinking water</td></tr><tr><td align="left" colspan="8">&#x000a0;Municipal</td></tr><tr><td align="left">&#x000a0;&#x000a0;Yes</td><td align="left">39 (95.1)</td><td align="left">456 (91.4)</td><td align="left">495 (91.7)</td><td align="left">1.84 (0.43&#x02013;7.88)</td><td align="left">0.563</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;&#x000a0;No</td><td align="left">2 (4.9)</td><td align="left">43 (8.6)</td><td align="left">45 (8.3)</td><td align="left">Ref</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left" colspan="8">&#x000a0;Borehole</td></tr><tr><td align="left">&#x000a0;&#x000a0;Yes</td><td align="left">2 (4.9)</td><td align="left">43 (8.6)</td><td align="left">45 (8.3)</td><td align="left">0.54 (0.13&#x02013;2.33)</td><td align="left">0.563</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;&#x000a0;No</td><td align="left">39 (95.1)</td><td align="left">456 (91.4)</td><td align="left">495 (91.7)</td><td align="left">Ref</td><td align="left"/><td align="left"/><td align="left"/></tr></tbody></table><table-wrap-foot><p><italic>cOR</italic> crude odds ratio,<italic> CI</italic> confidence interval,<italic> Ref</italic> reference category,<italic> aOR</italic> adjusted odds ratio.</p><p>*Significant at 0.05.</p></table-wrap-foot></table-wrap>
</p></sec></sec></sec><sec id="Sec15" sec-type="discussion"><title>Discussion</title><p id="Par45">In this study, all carbapenem-resistant Enterobacterales (CRE) were carbapenemase producers. Similar findings were reported in a Nairobi-City County hospital in Kenya<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>. In other studies, Li and colleagues (2024) found that all CRE among adults from four provinces of China encoding carbapenemase genes<sup><xref ref-type="bibr" rid="CR23">23</xref></sup>, while Davari et al. found 95.2% of CRE isolates from patients admitted to intensive care unit (ICU) in Southern Iran were CPE<sup><xref ref-type="bibr" rid="CR24">24</xref></sup>. The gastrointestinal (GI) carriage rate of carbapenemase-producing Enterobacterales <italic>(</italic>CPE) in the current study was higher among inpatients (9.6%), than outpatients (5.9%,) under the age of five years. Transmission of CRE is frequent in healthcare settings compared to community settings<sup><xref ref-type="bibr" rid="CR25">25</xref></sup>, with healthcare providers playing a role in the acquisition among hospitalized patients<sup><xref ref-type="bibr" rid="CR26">26</xref>,<xref ref-type="bibr" rid="CR27">27</xref></sup>. The carriage rate among the inpatients (9.6%) in the current study was higher than the 2.25% asymptomatic carriage reported among children (&#x02264;&#x02009;5 y) admitted in Mama Lucy Kibaki in Nairobi, Kenya<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>and 7.3% adult patients in Saint Paul&#x02019;s Hospital Millennium Medical College, Addis Ababa, Ethiopia<sup><xref ref-type="bibr" rid="CR28">28</xref></sup>. However, in our study CPE gastrointestinal carriage of 9.6% was lower than 28% documented among admitted patients in a tertiary care hospital in Egypt<sup><xref ref-type="bibr" rid="CR29">29</xref></sup>.</p><p id="Par46">Among outpatients, CPE gastrointestinal carriage was 5.9% which was lower than 9% reported among children and adult&#x02019;s household contacts of CPE cases in Ontario, Canada<sup><xref ref-type="bibr" rid="CR30">30</xref></sup>, but higher than 0.6% CRE reported carriage rate in rural communities in Vietnam<sup><xref ref-type="bibr" rid="CR31">31</xref></sup> and 3.6% in outpatient children in Shanghai<sup><xref ref-type="bibr" rid="CR32">32</xref></sup>. The discordance in these study findings could result from differences in methodology and geographical variation in the epidemiology of CRE<sup><xref ref-type="bibr" rid="CR25">25</xref>,<xref ref-type="bibr" rid="CR33">33</xref></sup> based on local antibiotic prescribing practices, the misuse or overuse of carbapenems, personal and environmental hygiene, and insufficient infection prevention and control (IPC) strategies within healthcare settings. The carbapenem resistance is mediated by carbapenemases, a group of enzymes encoded on mobile genetic elements, allowing rapid spread and extensive distribution of the resistance traits among bacterial pathogens, escalating antimicrobial resistance (AMR)<sup><xref ref-type="bibr" rid="CR34">34</xref></sup>. In the current study setting, the high gastrointestinal of CPE carriage represents a significant public health threat due to the potential for heightened transmission, healthcare-associated outbreaks, and community infections with limited treatment options. Our study finding underscores the urgent need for a multifaceted approach involving improved infection control practices, antimicrobial stewardship, surveillance systems, and international collaboration in line with global and international action plans on antimicrobial resistance.</p><p id="Par47">In the current research, the CPE spectrum included five bacterial species recovered from outpatients and four from inpatients. Carbapemase-producing (CP) <italic>Enterobacter cloacea</italic> and CP <italic>Klebsiella variicola</italic> were not isolated from outpatients, while CP <italic>Citrobacter freundii</italic>, CP <italic>Enterobacter bugandensis,</italic> and CP <italic>Proteus mirabilis</italic> were missing from the inpatient children. The bacterial spectrum in our study differs from that obtained from randomly selected infants (&#x0003c;&#x02009;1 year), children (1&#x02013;17 years), and adults (&#x02265;&#x02009;18 years) from a hospital and associated communities in Guatemala during the coronavirus disease 2019 (COVID-19) pandemic<sup><xref ref-type="bibr" rid="CR35">35</xref></sup>. We also found a co-carriage of <italic>E. coli</italic> and <italic>Klebsiella pneumoniae</italic> among inpatients (0.4%), consistent with a study that reported gastrointestinal carriage with multiple CRE isolates in the same patients<sup><xref ref-type="bibr" rid="CR36">36</xref></sup>.</p><p id="Par48"><italic>Escherichia coli</italic> was the predominant CPE in both inpatients (84.6%) and outpatients ( 62.5%). This finding is consistent with those of studies in the Northwest, Ethiopia<sup><xref ref-type="bibr" rid="CR37">37</xref></sup>, India<sup><xref ref-type="bibr" rid="CR38">38</xref></sup>, and Guatemala<sup><xref ref-type="bibr" rid="CR35">35</xref></sup>, where <italic>E. coli</italic> was the most common gastrointestinal carbapenemase-resistant isolate. Contrarily to our study finding, <italic>Enterobacter cloacae</italic> was the predominant CPE isolate reported in Addis Ababa, Ethiopia<sup><xref ref-type="bibr" rid="CR28">28</xref></sup>, and <italic>E. coli</italic> and <italic>Enterobacter cloacae subsp dissolvens</italic> in a recent study in Nairobi, Kenya<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>. The spectrum of carbapenemase-resistant bacteria and level of resistance can vary geographically depending on the genetic makeup of bacterial populations, differences in antibiotic usage patterns, adherence to infection control in healthcare settings and antimicrobial stewardship policies, human travel and migration, and environmental factors such as sanitation practices and agricultural antibiotic use. Effective interventions to combat the spread of the carbapenemase-producing bacteria found in this study remain critical.</p><p id="Par49">In the current study, CPEC resistance to third-generation cephalosporins (3GCs), including ceftriaxone, ceftazidime and cefotaxime, was 100% in both outpatient and inpatient department. Resistance to aminoglycosides (gentamicin (GEN) and amikacin (AMK)) was highest in CPEC isolates from inpatients (32%) compared with those from outpatients (10%). All the isolates from inpatient (100%) and 80% of those recovered from outpatient were multidrug-resistant. Previous studies have documented higher drug-resistant bacteria in hospitals than in community settings<sup><xref ref-type="bibr" rid="CR39">39</xref>,<xref ref-type="bibr" rid="CR40">40</xref></sup>. Hospitalized patients are more likely to harbour drug-resistant bacteria due to frequent antibiotic use, a high number of vulnerable patient populations, and the complex and dynamic environment that creates a conducive niche for the emergence and spread of drug-resistant organisms.</p><p id="Par50">Our study finding on 3GC resistance was similar to that reported in CRE stool isolates from adults in China<sup><xref ref-type="bibr" rid="CR23">23</xref></sup>, children in Shanghai<sup><xref ref-type="bibr" rid="CR41">41</xref></sup> and infants, children and adults in Guatemala<sup><xref ref-type="bibr" rid="CR35">35</xref></sup>. Other studies have reported lower resistance levels of ceftriaxone (0%) in Hunan, China<sup><xref ref-type="bibr" rid="CR42">42</xref></sup> and ceftriaxone (59.6%), cefotaxime (67.3%), and ceftazidime (94.2%) in Northwest Ethiopia<sup><xref ref-type="bibr" rid="CR37">37</xref></sup> among CRE stool isolates from hospitalized patients. Extended-spectrum beta-lactamase (ESBL)-producing Enterobacterales, defined by resistance to 3GCs, fourth-generation cephalosporins (4GCs), and monobactams, are among the World Health Organization (WHO) top-priority pathogens that require urgent development of antibiotics<sup><xref ref-type="bibr" rid="CR43">43</xref></sup>. In addition to 3GC resistance, CPEC isolates in the current study were 60&#x02013;91% cefepime (4GCs)-resistant and 100% monobactam (aztreonan)-resistant, suggesting the presence of ESBL-producing phenotypes.</p><p id="Par51">The 3GC resistance in the current study represents a significant public health threat since these isolates were multidrug-resistant and produced carbapenemases, enzymes that inactivate the carbapenems, the antibiotics considered &#x02018;the last resort&#x02019; for treating multidrug-resistant organisms. Multiple antibiotic resistance indices (MARI) of the isolates were high, ranging from 0.23 to 0.46. The high MARI (&#x0003e;&#x02009;0.2) in the current study indicated that the CPEC isolates had prior exposure to multiple antibiotic environments and were more likely to cause difficult-to-treat infections<sup><xref ref-type="bibr" rid="CR44">44</xref></sup>. However, these isolates remained susceptible to colistin, a finding consistent with Liu et al. in Hunan, China<sup><xref ref-type="bibr" rid="CR42">42</xref></sup>. Elsewhere, colistin resistance in CRE stool isolates is documented among adults (1.47%) in China<sup><xref ref-type="bibr" rid="CR45">45</xref></sup> and children (9.4%) in Shanghai<sup><xref ref-type="bibr" rid="CR41">41</xref></sup>. Our study finding highlights the clinical relevance of colistin and the need for ongoing antibiotic stewardship, infection control, and public health strategies to combat AMR resistance and secure public health in current and similar settings.</p><p id="Par52">Children (&#x02264;&#x02009;5 years) presenting with chills symptoms were four times more likely to have CPE gastrointestinal colonization when compared with those without such a symptom. Chills are traditionally associated with severe bacterial infections and bacteremia<sup><xref ref-type="bibr" rid="CR46">46</xref></sup>. Intestinal CRE colonization may precede infection among susceptible individuals, such as those with weakened immunity, admitted to intensive care units (ICU), artificially ventilated, and catheterization<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>. Additionally, gastrointestinal bacteria that have acquired antimicrobial resistance genes can degrade antibiotics, shielding pathogens from the bactericidal effects of antibiotics<sup><xref ref-type="bibr" rid="CR47">47</xref></sup>. Enhanced environmental cleaning, strict adherence to hand hygiene protocols, patient isolation, and screening for colonization are required to prevent CRE transmission during hospital stays.</p><p id="Par53">This study had some limitations in that we did not elucidate the molecular characteristics of the isolates due to financial constraints and identify the factors associated with the colonization among the outpatients, perhaps due to a small study sample.</p></sec><sec id="Sec16" sec-type="conclusion"><title>Conclusion</title><p id="Par54">We observed a significant gastrointestinal carriage of carbapenem-resistant Enterobacterales (CRE) that were carbapenemase producers among inpatient and outpatient children (&#x02264;&#x02009;5 years), with chills as a predictor of colonization among the hospitalized participants. It is critical to conduct antimicrobial resistance surveillance, through routine screening of clinical isolates for CPE production and adhere to antimicrobial stewardship policies to control CRE dissemination in the current study setting and beyond.</p></sec><sec id="Sec120" sec-type="supplementary-material"><title>Electronic supplementary material</title><p>Below is the link to the electronic supplementary material.</p><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="41598_2024_78059_MOESM1_ESM.docx"><caption><p>Supplementary Material 1</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We express our appreciation for the commendable efforts of Elizabeth Wamuyu and Joan Maina from Thika Level 5 Hospital, who played a pivotal role in coordinating and aiding in the collection of samples for this research study. We also extend our gratitude to the National Microbiology Reference Laboratory Team for their valuable assistance in the technical aspects of this study.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>SG, JMM, and AMM conceived and developed the study protocol, and interpreted the data. SG drafted and AMM reviewed the manuscript; TN and CN assisted in the laboratory work. KWN assisted in the data analysis. All the authors read and approved the final manuscript.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The datasets utilized in this study can be acquired from the corresponding author upon request.</p></notes><notes><title>Declarations</title><notes id="FPar5" notes-type="COI-statement"><title>Competing interests</title><p id="Par57">The authors declare no competing interests.</p></notes><notes id="FPar3"><title>Ethics approval and consent to participate</title><p id="Par55">The study was approved by Kenyatta University&#x02019;s ethical research committee, reference number (PKU/2620/E1745) as well as the National Commission of Science, Technology, and Innovation (NACOSTI), reference number (P/22/22147). Approval for collection of samples was obtained from Ethical Research Committee, Thika Level 5 hospital (Ref. MOH/TKA/GEN/VOL. VI/017). Additionally, the parent or guardian of each child who participated in the study gave their informed consent. Results and patient identification were both kept confidential. The findings of this study will guide in infection prevention and control interventions which will minimise infections of the patients. The findings will also guide in the correct selection of the antibiotics for treating the patients.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Murray</surname><given-names>CJ</given-names></name><etal/></person-group><article-title>Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis</article-title><source>Lancet</source><year>2022</year><volume>399</volume><fpage>629</fpage><lpage>655</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(21)02724-0</pub-id><pub-id pub-id-type="pmid">35065702</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Murray, C. J. et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. <italic>Lancet</italic><bold>399</bold>, 629&#x02013;655 (2022).<pub-id pub-id-type="pmid">35065702</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="other">O&#x02019;Neill, J. Antimicrobial resistance: tackling a crisis for the health and wealth of nations. Review on antimicrobial resistance. <italic>Rev. Antimicrob. Resist.</italic>, 1&#x02013;6 (2014).</mixed-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="other">WHO. Global action plan on antimicrobial resistance (2015). <ext-link ext-link-type="uri" xlink:href="https://www.who.int/publications/i/item/9789241509763">https://www.who.int/publications/i/item/9789241509763</ext-link></mixed-citation></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="other">Ning, N. et al. Molecular epidemiology of Bla OXA-23-producing carbapenemase-resistant Acinetobacter baumannii in a single institution over a 65-month period in north China. <italic>BMC Infect. Dis.</italic><bold>17</bold> (2017).</mixed-citation></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Karah</surname><given-names>N</given-names></name><name><surname>Dwibedi</surname><given-names>CK</given-names></name></person-group><article-title>Novel aminoglycoside resistance transposons and transposon-derived circular forms detected in carbapenemase-resistant Acinetobacter baumannii clinical isolates</article-title><source>Antimicrob. Agents Chemother.</source><year>2016</year><volume>60</volume><issue>3</issue><fpage>1801</fpage><lpage>1818</lpage><pub-id pub-id-type="doi">10.1128/AAC.02143-15</pub-id><pub-id pub-id-type="pmid">26824943</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Karah, N. &#x00026; Dwibedi, C. K. Novel aminoglycoside resistance transposons and transposon-derived circular forms detected in carbapenemase-resistant Acinetobacter baumannii clinical isolates. <italic>Antimicrob. Agents Chemother.</italic><bold>60</bold>(3), 1801&#x02013;1818 (2016).<pub-id pub-id-type="pmid">26824943</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Asokan</surname><given-names>GV</given-names></name><name><surname>Ramadhan</surname><given-names>T</given-names></name><name><surname>Ahmed</surname><given-names>E</given-names></name><name><surname>Sanad</surname><given-names>H</given-names></name></person-group><article-title>WHO Global Priority pathogens list: a bibliometric analysis of Medline-PubMed for knowledge mobilization to infection prevention and control practices in Bahrain</article-title><source>Oman Med. J.</source><year>2019</year><volume>34</volume><fpage>3</fpage><pub-id pub-id-type="doi">10.5001/omj.2019.37</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Asokan, G. V., Ramadhan, T., Ahmed, E. &#x00026; Sanad, H. WHO Global Priority pathogens list: a bibliometric analysis of Medline-PubMed for knowledge mobilization to infection prevention and control practices in Bahrain. <italic>Oman Med. J.</italic><bold>34</bold>, 3 (2019).</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Suay-Garc&#x000ed;a</surname><given-names>B</given-names></name><name><surname>P&#x000e9;rez-Gracia</surname><given-names>MT</given-names></name></person-group><article-title>Present and future of carbapenemase-resistant Enterobacterales (CRE) infections</article-title><source>Antibiot. 2019</source><year>2019</year><volume>8</volume><fpage>122</fpage></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Suay-Garc&#x000ed;a, B. &#x00026; P&#x000e9;rez-Gracia, M. T. Present and future of carbapenemase-resistant Enterobacterales (CRE) infections. <italic>Antibiot. 2019</italic>. <bold>8</bold>, 122 (2019).</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><mixed-citation publication-type="other">Saseedharan, S., Sahu, M., Pathrose, Joseph, E. &#x00026; Shivdas, S. Act fast as time is less: high faecal carriage of carbapenemase-resistant enterobacterales in critical care patients. <italic>J. Clin. Diagn.</italic><bold>10</bold>, DC01&#x02013;DC05 (2016).</mixed-citation></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="other">Garbati, M. A., Sakkijha, H. &#x00026; Abushaheen, A. Infections due to carbapenem resistant enterobacterales among Saudi Arabian hospitalized patients: a matched case-control study. <italic>Biomed. Res. Int.</italic> (2016).</mixed-citation></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="other">de Maio Carrilho, C. M. D. et al. A prospective study of treatment of carbapenemase-resistant enterobacterales infections and risk factors associated with outcome. <italic>BMC Infect. Dis.</italic><bold>16</bold> (2016).</mixed-citation></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="other">Lim, F. K. et al. Treatment and outcomes of infections caused by diverse Carbapenemase-producing carbapenemase-resistant Enterobacterales. <italic>Front. Cell Infect. Microbiol.</italic><bold>10</bold> (2020).</mixed-citation></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="other">Li, Y., Li, Z., Zhao, Q., Liu &#x00026; Li, B. Treatment options and clinical outcomes for carbapenemase-resistant Enterobacterales bloodstream infection in a Chinese university hospital&#x02019;. <italic>Infect. Public Health</italic><bold> 1</bold>, 26&#x02013;31 (2019).</mixed-citation></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Mutuma</surname><given-names>CK</given-names></name><name><surname>Maingi</surname><given-names>J</given-names></name><name><surname>Maina</surname><given-names>AK</given-names></name><name><surname>Njeru</surname><given-names>J</given-names></name><name><surname>Musyoki</surname><given-names>AM</given-names></name></person-group><article-title>Asymptomatic gastrointestinal carriage of multidrug-resistant carbapenemase-producing Enterobacteralesamong children under five years in a Kenyan hospital</article-title><source>IJID Reg.</source><year>2023</year><volume>9</volume><fpage>25</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1016/j.ijregi.2023.07.007</pub-id><pub-id pub-id-type="pmid">37818227</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Mutuma, C. K., Maingi, J., Maina, A. K., Njeru, J. &#x00026; Musyoki, A. M. Asymptomatic gastrointestinal carriage of multidrug-resistant carbapenemase-producing Enterobacteralesamong children under five years in a Kenyan hospital. <italic>IJID Reg.</italic><bold>9</bold>, 25&#x02013;31 (2023).<pub-id pub-id-type="pmid">37818227</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Manenzhe</surname><given-names>RI</given-names></name><name><surname>Zar</surname><given-names>HJ</given-names></name><name><surname>Nicol</surname><given-names>MP</given-names></name><name><surname>Kaba</surname><given-names>M</given-names></name></person-group><article-title>The spread of carbapenemase-producing bacteria in Africa: a systematic review</article-title><source>J. Antimicrob. Chemother.</source><year>2015</year><volume>70</volume><fpage>23</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1093/jac/dku356</pub-id><pub-id pub-id-type="pmid">25261423</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Manenzhe, R. I., Zar, H. J., Nicol, M. P. &#x00026; Kaba, M. The spread of carbapenemase-producing bacteria in Africa: a systematic review. <italic>J. Antimicrob. Chemother.</italic><bold>70</bold>, 23&#x02013;40 (2015).<pub-id pub-id-type="pmid">25261423</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Mitgang</surname><given-names>EA</given-names></name><name><surname>Hartley</surname><given-names>DM</given-names></name><name><surname>Malchione</surname><given-names>MD</given-names></name><name><surname>Koch</surname><given-names>M</given-names></name><name><surname>Goodman</surname><given-names>JL</given-names></name></person-group><article-title>Review and mapping of carbapenemase-resistant enterobacterales in Africa: using diverse data to inform surveillance gaps</article-title><source>Int. J. Antimicrob. Agents</source><year>2018</year><volume>52</volume><fpage>372</fpage><lpage>384</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2018.05.019</pub-id><pub-id pub-id-type="pmid">29864500</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Mitgang, E. A., Hartley, D. M., Malchione, M. D., Koch, M. &#x00026; Goodman, J. L. Review and mapping of carbapenemase-resistant enterobacterales in Africa: using diverse data to inform surveillance gaps. <italic>Int. J. Antimicrob. Agents</italic><bold>52</bold>, 372&#x02013;384 (2018).<pub-id pub-id-type="pmid">29864500</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="other">Ssekatawa, K., Byarugaba, D. K., Wampande, E. &#x00026; Ejobi, F. A systematic review: the current status of carbapenem resistance in East Africa. <italic>BMC Res. Notes</italic><bold>11</bold> (2018).</mixed-citation></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="other">CDC. Carbapenemase-resistant Enterobacterales (CRE) infection: clinician FAQs (CDC, 2015). <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/hai/organisms/cre/cre-clinicianfaq.html">https://www.cdc.gov/hai/organisms/cre/cre-clinicianfaq.html</ext-link></mixed-citation></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Giannella</surname><given-names>ME</given-names></name><name><surname>Trecarichi</surname></name><name><surname>Rosa</surname><given-names>FD</given-names></name></person-group><article-title>Risk factors for carbapenemase-resistant Klebsiella pneumoniae bloodstream infection among rectal carriers: a prospective observational multicentre study</article-title><source>Clin. Microbiol. Infect.</source><year>2014</year><volume>20</volume><fpage>1357</fpage><lpage>1362</lpage><pub-id pub-id-type="doi">10.1111/1469-0691.12747</pub-id><pub-id pub-id-type="pmid">24980276</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Giannella, M. E., Trecarichi &#x00026; Rosa, F. D. Risk factors for carbapenemase-resistant Klebsiella pneumoniae bloodstream infection among rectal carriers: a prospective observational multicentre study. <italic>Clin. Microbiol. Infect.</italic><bold>20</bold>, 1357&#x02013;1362 (2014).<pub-id pub-id-type="pmid">24980276</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="other">Sanjeev, V. A. and M. S. K. Utilization of MacConkey-meropenem screening agar for the detection of carbapenem resistant Enterobacterales in a tertiary care hospital.<italic> Int. J. Med. Sci.</italic><bold>2</bold>(4), 2 (2015).</mixed-citation></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="other">CLSI Supplement M100. CLSI, performance standards for antimicrobial susceptibility testing, 33rd edn (Clinical and Laboratory Standards Institute, 2023).</mixed-citation></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Rudresh</surname><given-names>SM</given-names></name><name><surname>Nagarathnamma</surname><given-names>T</given-names></name></person-group><article-title>Extended spectrum &#x003b2;-lactamase producing enterobacterales &#x00026; antibiotic co-resistance</article-title><source>Indian J. Med. Res.</source><year>2011</year><volume>133</volume><fpage>116</fpage><lpage>118</lpage><pub-id pub-id-type="pmid">21321429</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Rudresh, S. M. &#x00026; Nagarathnamma, T. Extended spectrum &#x003b2;-lactamase producing enterobacterales &#x00026; antibiotic co-resistance. <italic>Indian J. Med. Res.</italic><bold>133</bold>, 116&#x02013;118 (2011).<pub-id pub-id-type="pmid">21321429</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="other">Choudhury, D., Singh, N., Rai, S., Batra, P. &#x00026; Manchanda, V. Carbapenem resistant EnterobacteralesNeonatal gut colonization: A future concern in healthcare settings. <italic>Indian J Microbiol Res.</italic><bold> 5</bold>, 348&#x02013;354 (2018).</mixed-citation></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="other">Li, Y., Ma, L., Ding, X. &#x00026; Zhang, R. Fecal carriage and genetic characteristics of carbapenemase-resistant enterobacterales among adults from four provinces of China. <italic>Front. Epidemiol.</italic><bold>3</bold> (2024).</mixed-citation></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Davari</surname><given-names>N</given-names></name><name><surname>Khashei, Pourabbas</surname><given-names>R</given-names></name><name><surname>Nikbin</surname><given-names>V</given-names></name></person-group><article-title>High frequency of carbapenemase-resistant enterobacteralesfecal carriage among ICU hospitalized patients from Southern Iran</article-title><source>Iran. J. Basic Med. Sci.</source><year>2022</year><volume>25</volume><fpage>1416</fpage><lpage>1423</lpage><pub-id pub-id-type="pmid">36544530</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Davari, N., Khashei, Pourabbas, R. &#x00026; Nikbin, V. High frequency of carbapenemase-resistant enterobacteralesfecal carriage among ICU hospitalized patients from Southern Iran. <italic>Iran. J. Basic Med. Sci.</italic><bold>25</bold>, 1416&#x02013;1423 (2022).<pub-id pub-id-type="pmid">36544530</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Von Laer</surname><given-names>A</given-names></name><etal/></person-group><article-title>Geographical differences of carbapenem non-susceptible enterobacterales and Acinetobacter spp. in Germany from 2017 to 2019</article-title><source>Antimicrob. Resist. Infect. Control</source><year>2020</year><volume>11</volume><fpage>25</fpage><pub-id pub-id-type="doi">10.1186/s13756-021-01045-z</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Von Laer, A. et al. Geographical differences of carbapenem non-susceptible enterobacterales and Acinetobacter spp. in Germany from 2017 to 2019. <italic>Antimicrob. Resist. Infect. Control</italic>. <bold>11</bold>, 25 (2020).</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Goodman</surname><given-names>KP</given-names></name><name><surname>Simner</surname></name><name><surname>Klein</surname><given-names>E</given-names></name></person-group><article-title>How frequently are hospitalized patients colonized with carbapenemase-resistant Enterobacterales (CRE) already on contact precautions for other indications?</article-title><source>Infect. Control Hosp. Epidemiol.</source><year>2018</year><volume>39</volume><fpage>1491</fpage><lpage>1493</lpage><pub-id pub-id-type="doi">10.1017/ice.2018.236</pub-id><pub-id pub-id-type="pmid">30269700</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Goodman, K. P., Simner &#x00026; Klein, E. How frequently are hospitalized patients colonized with carbapenemase-resistant Enterobacterales (CRE) already on contact precautions for other indications? <italic>Infect. Control Hosp. Epidemiol.</italic><bold>39</bold>, 1491&#x02013;1493 (2018).<pub-id pub-id-type="pmid">30269700</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><mixed-citation publication-type="other">Grabowsk, M., Khang., H., Wells., K., Sifri, C., Mathers, A. &#x00026; Lobo, J. Provider role in transmission of carbapenemase-resistant Enterobacterales. <italic>Infect. Control Hosp. Epidemiol.</italic><bold>38</bold>, 1329&#x02013;1334 (2017).</mixed-citation></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Mekonnen</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Fecal carriage of carbapenem resistant Enterobacterales and associated factors among admitted patients in Saint Paul&#x02019;s Hospital Millennium Medical College, Addis Ababa, Ethiopia</article-title><source>Infect. Drug Resist.</source><year>2023</year><volume>16</volume><fpage>6345</fpage><lpage>6355</lpage><pub-id pub-id-type="doi">10.2147/IDR.S418066</pub-id><pub-id pub-id-type="pmid">37789843</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Mekonnen, Y. et al. Fecal carriage of carbapenem resistant Enterobacterales and associated factors among admitted patients in Saint Paul&#x02019;s Hospital Millennium Medical College, Addis Ababa, Ethiopia. <italic>Infect. Drug Resist.</italic><bold>16</bold>, 6345&#x02013;6355 (2023).<pub-id pub-id-type="pmid">37789843</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>El-Defrawy</surname><given-names>I</given-names></name><etal/></person-group><article-title>Detection of intestinal colonization by carbapenem-resistant <italic>Enterobacteriaceae</italic> (CRE) among patients admitted to a tertiary care hospital in Egypt</article-title><source>Egypt. J. Med. Hum. Genet.</source><year>2022</year><volume>23</volume><fpage>83</fpage><pub-id pub-id-type="doi">10.1186/s43042-022-00295-9</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">El-Defrawy, I. et al. Detection of intestinal colonization by carbapenem-resistant <italic>Enterobacteriaceae</italic> (CRE) among patients admitted to a tertiary care hospital in Egypt. <italic>Egypt. J. Med. Hum. Genet.</italic><bold>23</bold>, 83 (2022).</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><mixed-citation publication-type="other">Jamal, A. J. et al. Clinical Infectious Diseases Clinical Infectious Diseases&#x000ae;.<bold> 73</bold>(11), e4607-15 (2021). Household Transmission of Carbapenemase-producing Enterobacterales in Ontario, Canada. 10.1093/cid/ciaa1295.</mixed-citation></ref><ref id="CR31"><label>31.</label><mixed-citation publication-type="other">Thi, P. et al. Prevalence of carbapenem resistance and its potential association with antimicrobial use in humans and animals in rural communities in Vietnam. 10.1093/jacamr/dlac038</mixed-citation></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>F</given-names></name><etal/></person-group><article-title>Fecal carriage and molecular epidemiology of carbapenemase-resistant Enterobacterales from outpatient children in Shanghai</article-title><source>BMC Infect. Dis.</source><year>2019</year><volume>19</volume><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1186/s12879-019-4298-3</pub-id><pub-id pub-id-type="pmid">30606108</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Pan, F. et al. Fecal carriage and molecular epidemiology of carbapenemase-resistant Enterobacterales from outpatient children in Shanghai. <italic>BMC Infect. Dis.</italic><bold>19</bold>, 1&#x02013;6 (2019).<pub-id pub-id-type="pmid">30606108</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Xu</surname><given-names>T</given-names></name><name><surname>Xia</surname><given-names>W</given-names></name></person-group><article-title>Epidemiology of carbapenem resistant enterobacterales (CRE) during 2000&#x02013;2012 in Asia</article-title><source>J. Thorac. Dis.</source><year>2015</year><volume>7</volume><fpage>376</fpage><lpage>385</lpage><pub-id pub-id-type="pmid">25922715</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Xu, Y., Huang., M., Liu., H., Xu, T. &#x00026; Xia, W. Epidemiology of carbapenem resistant enterobacterales (CRE) during 2000&#x02013;2012 in Asia. <italic>J. Thorac. Dis</italic>. <bold>7</bold>, 376&#x02013;385 (2015).<pub-id pub-id-type="pmid">25922715</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Meletis</surname><given-names>G</given-names></name></person-group><article-title>Carbapenem resistance: overview of the problem and future perspectives</article-title><source>Ther. Adv. Infect. Dis.</source><year>2016</year><volume>1</volume><fpage>15</fpage><lpage>21</lpage></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Meletis, G. Carbapenem resistance: overview of the problem and future perspectives. <italic>Ther. Adv. Infect. Dis.</italic><bold>1</bold>, 15&#x02013;21 (2016).</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Ramay</surname><given-names>BM</given-names></name><etal/></person-group><article-title>Colonization with antibiotic-resistant bacteria in a hospital and associated communities in Guatemala: an antibiotic resistance in communities and hospitals (ARCH) study</article-title><source>Clin. Infect. Dis.</source><year>2023</year><volume>77</volume><fpage>S82</fpage><pub-id pub-id-type="doi">10.1093/cid/ciad222</pub-id><pub-id pub-id-type="pmid">37406049</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Ramay, B. M. et al. Colonization with antibiotic-resistant bacteria in a hospital and associated communities in Guatemala: an antibiotic resistance in communities and hospitals (ARCH) study. <italic>Clin. Infect. Dis.</italic><bold>77</bold>, S82 (2023).<pub-id pub-id-type="pmid">37406049</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><mixed-citation publication-type="other">Timileyin, A. et al. Epidemiologic and microbiologic characteristics of hospitalized patients co-colonized with multiple species of Carbapenemase-Resistant Enterobacteralesin the United States. <italic>Open Forum Infect. Dis.</italic><bold>7</bold> (2020).</mixed-citation></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Tijet</surname><given-names>N</given-names></name><name><surname>Richardson</surname><given-names>D</given-names></name><name><surname>MacMullin</surname><given-names>G</given-names></name><name><surname>Patel</surname><given-names>SN</given-names></name><name><surname>Melano</surname><given-names>RG</given-names></name></person-group><article-title>Characterization of multiple NDM-1-producing Enterobacterales isolates from the same patient</article-title><source>Antimicrob. Agents Chemother.</source><year>2015</year><volume>59</volume><fpage>3648</fpage><lpage>3651</lpage><pub-id pub-id-type="doi">10.1128/AAC.04862-14</pub-id><pub-id pub-id-type="pmid">25845877</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Tijet, N., Richardson, D., MacMullin, G., Patel, S. N. &#x00026; Melano, R. G. Characterization of multiple NDM-1-producing Enterobacterales isolates from the same patient. <italic>Antimicrob. Agents Chemother.</italic><bold>59</bold>, 3648&#x02013;3651 (2015).<pub-id pub-id-type="pmid">25845877</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>V</given-names></name></person-group><article-title>Gastrointestinal colonization with multiple New Delhi metallo-&#x003b2;lactamase-producing Enterobacterales isolates in the same patient: a potential challenge in outbreak investigation</article-title><source>J. Hosp. Infect.</source><year>2016</year><volume>92</volume><fpage>108</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1016/j.jhin.2015.10.011</pub-id><pub-id pub-id-type="pmid">26615458</pub-id>
</element-citation><mixed-citation id="mc-CR38" publication-type="journal">Cheng, V. Gastrointestinal colonization with multiple New Delhi metallo-&#x003b2;lactamase-producing Enterobacterales isolates in the same patient: a potential challenge in outbreak investigation. <italic>J. Hosp. Infect.</italic><bold>92</bold>, 108&#x02013;109 (2016).<pub-id pub-id-type="pmid">26615458</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Girlich</surname><given-names>D</given-names></name><etal/></person-group><article-title>Multiple colonization with highly resistant bacteria: Carbapenemase-producing enterobacterales, carbapenemase-producing Pseudomonas aeruginosa, carbapenemase-producing Acinetobacter baumannii, and glycopeptide-resistant Enterococcus faecium</article-title><source>Diagn. Microbiol. Infect. Dis.</source><year>2015</year><volume>81</volume><fpage>217</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1016/j.diagmicrobio.2014.12.002</pub-id><pub-id pub-id-type="pmid">25547540</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Girlich, D. et al. Multiple colonization with highly resistant bacteria: Carbapenemase-producing enterobacterales, carbapenemase-producing Pseudomonas aeruginosa, carbapenemase-producing Acinetobacter baumannii, and glycopeptide-resistant Enterococcus faecium. <italic>Diagn. Microbiol. Infect. Dis.</italic><bold>81</bold>, 217&#x02013;218 (2015).<pub-id pub-id-type="pmid">25547540</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><mixed-citation publication-type="other">Kiros, T. et al. Carriage of &#x003b2;-lactamase and carbapenemase-producing enterobacterales in hospitalized patients at debre tabor comprehensive specialized hospital. <italic>Heliyon</italic><bold>9</bold> (2023).</mixed-citation></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Kumari</surname><given-names>PR</given-names></name></person-group><article-title>Detection of carbapenemase-resistant Enterobacterales by real-time PCR and assessment of hospitalization related risk factors associated with their fecal carriage: a case-control study</article-title><source>J. Pure Appl. Microbiol.</source><year>2022</year><volume>16</volume><fpage>1111</fpage><lpage>1121</lpage><pub-id pub-id-type="doi">10.22207/JPAM.16.2.37</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Kumari, P. R. Detection of carbapenemase-resistant Enterobacterales by real-time PCR and assessment of hospitalization related risk factors associated with their fecal carriage: a case-control study. <italic>J. Pure Appl. Microbiol.</italic><bold>16</bold>, 1111&#x02013;1121 (2022).</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Omulo</surname><given-names>S</given-names></name><etal/></person-group><article-title>Risk factors for colonization with extended-spectrum cephalosporin-resistant and carbapenemase-resistant enterobacterales among hospitalized patients in Kenya: an antibiotic resistance in communities and hospitals (ARCH) study</article-title><source>Clin. Infect. Dis.</source><year>2023</year><volume>77</volume><fpage>S97</fpage><lpage>S103</lpage><pub-id pub-id-type="doi">10.1093/cid/ciad258</pub-id><pub-id pub-id-type="pmid">37406042</pub-id>
</element-citation><mixed-citation id="mc-CR42" publication-type="journal">Omulo, S. et al. Risk factors for colonization with extended-spectrum cephalosporin-resistant and carbapenemase-resistant enterobacterales among hospitalized patients in Kenya: an antibiotic resistance in communities and hospitals (ARCH) study. <italic>Clin. Infect. Dis.</italic><bold>77</bold>, S97&#x02013;S103 (2023).<pub-id pub-id-type="pmid">37406042</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><mixed-citation publication-type="other">Ita, T. et al. Prevalence of colonization with multidrug-resistant bacteria in communities and hospitals in Kenya. <italic>Sci. Rep.</italic><bold>12</bold> (2022).</mixed-citation></ref><ref id="CR44"><label>44.</label><mixed-citation publication-type="other">Pan, F. et al. Fecal carriage and molecular epidemiology of carbapenemase-resistant Enterobacterales from outpatient children in Shanghai. 10.1186/s12879-019-4298-3</mixed-citation></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Fecal carriage and epidemiology of carbapenemase-resistant enterobacterales among hospitalized patients in a university hospital</article-title><source>Infect. Drug Resist.</source><year>2019</year><volume>12</volume><fpage>3935</fpage><lpage>3942</lpage><pub-id pub-id-type="doi">10.2147/IDR.S233795</pub-id><pub-id pub-id-type="pmid">31908504</pub-id>
</element-citation><mixed-citation id="mc-CR45" publication-type="journal">Liu, Q. et al. Fecal carriage and epidemiology of carbapenemase-resistant enterobacterales among hospitalized patients in a university hospital. <italic>Infect. Drug Resist.</italic><bold>12</bold>, 3935&#x02013;3942 (2019).<pub-id pub-id-type="pmid">31908504</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>Asokan</surname><given-names>GV</given-names></name></person-group><article-title>WHO Global Priority pathogens list: a bibliometric analysis of Medline-PubMed for Knowledge mobilization to Infection Prevention and Control Practices in Bahrain</article-title><source>Oman Med. J.</source><year>2019</year><volume>34</volume><fpage>184</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.5001/omj.2019.37</pub-id><pub-id pub-id-type="pmid">31110624</pub-id>
</element-citation><mixed-citation id="mc-CR46" publication-type="journal">Asokan, G. V. WHO Global Priority pathogens list: a bibliometric analysis of Medline-PubMed for Knowledge mobilization to Infection Prevention and Control Practices in Bahrain. <italic>Oman Med. J.</italic><bold>34</bold>, 184&#x02013;193 (2019).<pub-id pub-id-type="pmid">31110624</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><mixed-citation publication-type="other">Maina, J. W., Mutua, J. M. &#x00026; Musyoki, A. M. Carbapenemase-resistant gram-negative bacterial infections and risk factors for acquisition in a Kenyan intensive care unit. <italic>BMC Infect. Dis.</italic><bold>24</bold> (2024).</mixed-citation></ref></ref-list></back></article>